These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 24554781

  • 1. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [Abstract] [Full Text] [Related]

  • 2. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.
    Sci Rep; 2018 Nov 22; 8(1):17239. PubMed ID: 30467317
    [Abstract] [Full Text] [Related]

  • 3. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF.
    Eur J Cancer; 2016 Jan 22; 52():109-19. PubMed ID: 26682870
    [Abstract] [Full Text] [Related]

  • 4. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA.
    Mol Cancer Ther; 2012 Dec 22; 11(12):2633-43. PubMed ID: 23012248
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.
    Mol Cancer Res; 2014 Jul 22; 12(7):1042-54. PubMed ID: 24784839
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Patel K, Wen J, Magliocca K, Muller S, Liu Y, Chen ZG, Saba N, Diaz R.
    Cancer Chemother Pharmacol; 2014 Nov 22; 74(5):1015-22. PubMed ID: 25205430
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
    Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF.
    Mol Cancer Ther; 2017 May 22; 16(5):793-804. PubMed ID: 28167505
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC, Min HY, Choi H, Kim HS, Kim KC, Park SJ, Seong MA, Seo JH, Park HJ, Suh YG, Kim KW, Hong HS, Kim H, Lee MY, Lee J, Lee HY.
    Mol Pharmacol; 2015 Aug 22; 88(2):245-55. PubMed ID: 25976766
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
    Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH.
    Clin Cancer Res; 2016 Dec 01; 22(23):5876-5886. PubMed ID: 27354472
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
    Lin SF, Lin JD, Hsueh C, Chou TC, Yeh CN, Chen MH, Wong RJ.
    Oncotarget; 2017 Jun 20; 8(25):41294-41304. PubMed ID: 28476040
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.